Page 81 - MemoriaEHD-Eng

www.ciberehd.org

- Collaboration in the preparation of a “clean” HDV-RNA standard for its real-time

PCR quantification.

• Hepatitis E Virus (HEV) infection.

• New strategies for the treatment of chronic hepatitis B and C.

• Pharmacoeconomics.

• s Ms, p F, M Mp, B Jp, r r K, h sa.
Most relevant uLKoWsKioorDaDaNNsroNoWiCKiaJeNDereDDyarrisoN
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analy-
scientific
sis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.Hepatology. 2013
articles
Mar;57(3):974-84.

• FrieD MW, Buti M, Dore gJ, FLisiaK r, FereNCi p, JaCoBsoN i. Once-daily simeprevir

(TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 he-
patitis C: the randomized PILLAR study.Hepatology. 2013 Dec;58(6):1918-29.
í

• z s, s v, a t, B Jp, L aW, M B. Faldaprevir and
euzeMoriaNosseLahroNoWiCKiohseüLLhaupt
deleobuvir for HCV genotype 1 infection.N Engl J Med. 2013 Aug 15;369(7):630-9.

• raMrez C, gregori J, Buti M, taBerNero D, CaMós s, CasiLLas r. A comparative study of
ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies

using hepatitis B virus infection as a model.Antiviral Res. 2013 May;98(2):273-83.

• MarCeLLiN p, gaNe e, Buti M, aFDhaL N, sievert W, JaCoBsoN iM. Regression of cirrhosis

during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year
open-label follow-up study.Lancet. 2013 Feb 9;381(9865):468-75.

Highlights
During 2013 we have made progresses in standardizing ultra-deep pyrosequencing
and implementing it to clinical practice in viral hepatitis B and C. In this sense we

have continued our collaboration in the CDTI project (IDI - 20110115 ), which has

been completed in 2013, within which have been developed primers and methods
for the study of HCV quasispecies of which a patent is being processed (patent re-

quest EP13382278). Also we have started to apply this technology to the study of

quasispecies of hepatitis D and E viruses.

In line with the study of hepatitis D virus, we have continued international colla-
borations with groups of doctors Petersen and Dandri (Hamburg , Germany) and

Roggendorf (Munich, Germany) and have established a new partnership with the
hepatitis delta international network (HDIN) to include clinical data into its data

base. It is also remarkable our collaboration with the German network for excellence

in the treatment of viral hepatitis (Hep-Net).

Nationally, we coordinate and manage the platform for collecting clinical data of
chronic hepatitis B (CIBERHEP) which have collected data from nearly 1,000 pa-
13
tients with chronic hepatitis B, most of them under antiviral treatment with tenofovir 20
T
or entecavir (first-line treatment options against chronic hepatitis B). The analysis of OR
part of the data collected in this platform was accepted for oral presentation at the P
RE
39th annual meeting of the AEEH (2014).
L
A
We have also continued to participate in clinical trials of new direct action antiviral NU
treatments against hepatitis C. These studies have led to publications in high impact N
A
factor journals, some of which are listed among the 5 publications that we have D /
H
selected this year.
E
ER
IB
C

81